Cancer Treatments Have Very Few Toxic Side Effects

June 2014
Thomson Reuters Predicts What the World Will Be Like in 2025
Cancer Treatments Have Very Few Toxic Side Effects

Drug development is so much more precise, binding to specific proteins and using antibodies to give exact mechanisms of action, that the debilitating effects of toxic chemicals on patients is significantly reduced.

For a look ahead, Thomson Reuters analysts consulted the Web of Science and Derwent World Patents Index to identify rapid progress and emergent trends in scientific research and technological innovation, gauging the advances most likely to affect health and the quality of life in the next decade.

Download the full report or see the 10 predictions.

For patients undergoing treatment for cancer and other diseases, the specific targeting and precise molecular action of drug compounds will reduce toxicity and improve efficacy.

Just as Big Data is enabling companies to deliver personalized customer experiences, so too is life sciences moving from broad-brush drugs to very accurate and targeted treatments that result in significantly improved patient experiences.

This personalized medicine movement is not new. For several years the pharmaceutical community has been working on therapies that target specific molecules and perform targeted functions. Many drugs are now developed from biotechnology and are aimed at treating specific forms of a disease.

What will be new is the availability of drugs that reduce the complications associated with certain treatments. Drugs in development are becoming so targeted that they can bind to specific proteins and use antibodies to give precise mechanisms of action. Knowledge of specific gene mutations will be so much more advanced that scientists and physicians can treat those specific mutations. Examples of this include HER2 (breast cancer), BRAF V600 (melanoma), and ROS1 (lung cancer), among many others.

In addition, advancements in antibody production and targeting will significantly improve certain cancer treatments, such as related to the safety and activity of anti- PD-L1 antibodies in patients with advanced cancer. 

The impact of these advancements will be that patients in 2025 will have much more targeted drug treatments that result in fewer toxic side effects.

"Intratumor heterogeneity and branched evolution are revealed by multiregion sequencing" cited 600 times in less than 2 years

"Safety, activity and immune correlates of anti-PD-1 antibody in cancer" cited 400+ times in two years

Note to Editors and Writers: For images and other resources, please visit our Editorial Resources page.

The data and citation records included in this report are from Thomson Reuters Web of ScienceTM. Web of ScienceTM is a registered trademark of Thomson Reuters. All rights reserved.